Table A2.

Studies assessing the histomorphometric results of platelet-rich fibrin used for two-stage maxillary sinus augmentation. Statistical significance (p < 0.05) is highlighted in bold. Abbreviations: maxillary sinus augmentation (MSA), randomized clinical trial (RCT), case series (CS), deproteinized bovine bone material (DBBM), leukocyte- and platelet-rich fibrin (L-PRF), titanium-prepared, platelet-rich fibrin (T-PRF), beta-tricalcium phosphate (ß-TCP), platelet-rich plasma (PRP), freeze-dried bone allograft (FDBA), not statistically significant (n.s.)

First Author	Year of Publication	Study Design	Intervention	Sample Size (MSA)	Biomaterials Used	New Bone Formation % (Mean ± Std. Deviation)	p-Value	Healing Time Prior Implant Placement (Month)
Pichotano	2019	RCT	two-stage MSA	12	DBBM + L-PRF	44.58 ± 13.9%	0.0087	4
				12	DBBM	30.02 ± 9.99%		8
Nizam	2018	RCT	two-stage MSA	13	DBBM + L-PRF	21.38 ± 8.78%	n.s.	6
				13	DBBM	21.25 ± 5.59%		6
Olgun	2018	RCT	two-stage MSA	10	T-PRF	16.58 ± 1.05%	0.611	4
				8	FDBA	17.28 ± 2.53%		6
Kilic	2017	RCT	two-stage MSA	9	ß-TCP	33.40 ± 10.43%	n.s.	6
				9	ß-TCP + PRP	34.83 ± 10.12%		6
				8	ß-TCP + PRF	32.03 ± 6.34%
Bolukbasi	2015	CS	two-stage MSA	17	DBBM + PRF	35.0 ± 8.60%	0.61	6
				15	DBBM	32.97 ± 9.71%		6
Zhang	2012	RCT	two-stage MSA	6	DBBM + PRF	18.35 ± 5.62%	0.138	6
				5	DBBM	12.95 ± 5.33%		6
Tatullo	2012	RCT	two-stage MSA	8	DBBM	26.44%	n.s.	3
				12	DBBM + PRF	22.79%		3
				8	DBBM	28.7%	n.s.	4
				12	DBBM + PRF	26.15%		4
				8	DBBM	38.97%	n.s.	5
				12	DBBM + PRF	37.06%		5
Choukroun	2006	CS	two-stage MSA	6	FDBA + PRF	20.95%	n.s.	4
				3	FDBA	20.306%		8